CA
NZ
UK
AU
IND
US
The company says third-quarter revenue is not otherwise expected to be affected, while additional on-hand inventory should support implant availability for physicians and patient treatment.
Skye Bioscience, Inc. (NASDAQ: SKYE) regained compliance with Nasdaq’s minimum bid-price requirement after its common stock recorded a closing bid price of at least $1.00 per share from August 24 through September 4. The development coincided with the termination of its Master Services Agreement …
TENAX Therapeutics, Inc. (NASDAQ: TENX) lists ING Groep N.V. And ING Capital Markets LLC at 0.00% beneficial ownership, with neither reporting person holding common stock as of September 11, 2026. The update covers the two entities’ passive ownership position in Tenax common stock.
Tenaya Therapeutics, Inc. (NASDAQ: TNYA) awarded Chief Medical Officer Tingley Whittemore 49,000 shares at $0 per share on September 10, 2026. Whittemore’s resulting holding stood at 263,073 shares. The same date also brought an award of 293,000 derivative securities, leaving Whittemore with 293,000 derivative …
Fitzgerald Thomas A received 185,000 derivative securities in Transcode Therapeutics, Inc (NASDAQ: RNAZ). on 9 September 2026. The award left his resulting derivative securities position at 185,000, with the transaction representing about 100.0% of that holding.
Tyra Biosciences, Inc. (NASDAQ: TYRA) recorded an insider purchase of 972 shares at $20.58 per share. Verjee Rehan’s resulting holding was 972 shares, with the transaction representing about 100.0% of that holding. The transaction took place on 9 September 2026.
Opus Genetics, Inc. (NASDAQ: IRD) CEO Magrath George exercised options for 392,157 shares at $1.15 per share on 9 September 2026. The exercise represented about 18.5% of his resulting share holding, which stood at 2,124,026 shares afterward.
Park Ha Biological Technology Co. Ltd. (NASDAQ: BYAH) raised approximately US $2,970,000 through a privatePlacementthat sold 1,080,000 Class A ordinary shares at $2.75 per share. The transaction also provides participating non-U.S. Investors with warrants covering 1,845,452 Class A ordinary shares.
Pharming Group N.V. (NASDAQ: PHAR) received U.S. FDA approval expanding Joenja’s use to children ages 4 to 11 with activated phosphoinositide 3-kinaseDeltasyndrome, or APDS, who weigh at least 27 kg.
SCYNEXIS INC (NASDAQ: SCYX) awarded Chief Financial Officer Subramanian Sanjay 100,000 derivative securities on Sep 9. The transaction left him with 100,000 derivative securities, according to the reported insider transaction.
Please wait processing your request...